Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Southern Energy Corp. Completes US$23.5 Million Financings and Royalty Sale (click to learn more) Cariboo Gold History Inspires Modern Discovery (CSE:GCC) (OTC:GCCFF) (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

ACADIA Pharmaceuticals Inc ACAD

Healthcare Biotechnology
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer’s disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatmen...


NDAQ:ACAD - Post by User

ACADIA Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(4)
•••
  • AviseAnalyticsX
Post by AviseAnalyticson Jun 22, 2022 7:27am
228 Views
Post# 34773204

ACADIA PHARMACEUTICALS: WHAT’S NEXT AFTER THE NEGATIVE FDA A

ACADIA PHARMACEUTICALS: WHAT’S NEXT AFTER THE NEGATIVE FDA A
$ACAD

Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central nervous system disorders, faced a setback at the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin, a drug intended to treat hallucinations and delusions associated with Alzheimer’s disease psychosis. 
 
We delve into what's next for the Company in our article today!

Read on to know more:

https://www.aviseanalytics.com/acadia-pharmaceuticals-whats-next-after-the-negative-fda-adcom/
 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities